Coding Bio Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Seed
- Investors
-
15
Coding Bio General Information
Description
Developer of a cell discovery platform designed to accelerate the development of new targets for chimeric antigen receptors. The company's platform uses artificial intelligence to design cell therapies through automation and computation, enabling patients to recover from illness with the help of curative therapeutics.
Contact Information
Website
www.coding.bioCorporate Office
- Gipsy Lane, Enterprise Centre
- Oxford OX3 0BP
- England, United Kingdom
Corporate Office
- Gipsy Lane, Enterprise Centre
- Oxford OX3 0BP
- England, United Kingdom
Coding Bio Timeline
Coding Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Seed Round | 13-Feb-2026 | Completed | Generating Revenue | |||
| 3. Seed Round | 05-Sep-2023 | Completed | Generating Revenue | |||
| 2. Seed Round | 13-Apr-2022 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Coding Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed 2 | ||||||||
| Seed | ||||||||
| Seed | 659,485 | $0.000127 | $3.75 | $3.75 | 1x | $3.75 | 27.64% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Coding Bio Patents
Coding Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202509058-D0 | Method for the identification of t-cell engagers | Pending | 09-Jun-2025 | ||
| EP-4805394-A1 | Bcma binding molecules | Pending | 07-Nov-2023 | ||
| GB-202317065-D0 | Bcma binding molecules | Inactive | 07-Nov-2023 | ||
| WO-2025099434-A1 | Bcma binding molecules | Inactive | 07-Nov-2023 | ||
| GB-202301949-D0 | Cll1 and/or cd33 binding molecules | Inactive | 10-Feb-2023 | C07K16/2803 |
Coding Bio Signals
Coding Bio Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bija Ventures | Venture Capital | Minority | ||
| Myeloma Investment Fund | Not-For-Profit Venture Capital | Minority | ||
| 2048 Ventures | Venture Capital | Minority | ||
| Divergent Capital | Impact Investing | Minority | ||
| Divergent Capital (New York) | Venture Capital | Minority |
Coding Bio FAQs
-
When was Coding Bio founded?
Coding Bio was founded in 2020.
-
Where is Coding Bio headquartered?
Coding Bio is headquartered in Oxford, United Kingdom.
-
What is the size of Coding Bio?
Coding Bio has 19 total employees.
-
What industry is Coding Bio in?
Coding Bio’s primary industry is Drug Discovery.
-
Is Coding Bio a private or public company?
Coding Bio is a Private company.
-
What is Coding Bio’s current revenue?
The current revenue for Coding Bio is .
-
How much funding has Coding Bio raised over time?
Coding Bio has raised $3.62M.
-
Who are Coding Bio’s investors?
Bija Ventures, Myeloma Investment Fund, 2048 Ventures, Divergent Capital, and Divergent Capital (New York) are 5 of 15 investors who have invested in Coding Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process